Employees: 1-10
Investment Stage: Seed; Series A; Series B
Portfolio 30
| Date | Name | Website | Total Raised | Location |
| 10.03.2024 | vTv Therap... | vtvtherapeutics.com | - | United Sta... |
| 10.03.2024 | Sana Biote... | sana.com | $2.79B | United Sta... |
| 10.05.2023 | DiogenX | diogenx.com | $35.2M | France, Pr... |
| 02.08.2022 | Egle Thera... | egle-tx.com | - | France, Il... |
| 13.08.2021 | GentiBio | gentibio.com | $177M | United Sta... |
| 21.07.2021 | Abata Ther... | abatatx.com | $95M | United Sta... |
| 16.07.2021 | Kriya Ther... | kriyatherapeutics.com | $370M | United Sta... |
| 05.09.2019 | Veralox Th... | veraloxtx.com | $5.4M | - |
| - | GluSense M... | glusensemedical.com | - | - |
| - | Pandion Th... | pandiontx.com | $138M | United Sta... |
Show more
Persons 7
| Date | First Name | Last Name | Title | Location | |||
| - | Matt | Williams | Director o... | - | - | - | |
| - | Clay | Rowland | Associate | linkedin.c... | - | c******d@t... | - |
| - | Nandan | Padukone | - | linkedin.c... | - | N*******e@... | - |
| - | Sean | O'Connor | Principal | - | - | - | |
| - | Katie | Ellias | Managing D... | linkedin.c... | - | k*****s@t1... | - |
| - | Yury | Kukushkin | - | linkedin.c... | - | y********n... | - |
| - | William | Orent | Associate | linkedin.c... | - | w****t@t1d... | - |
Mentions in press and media 19
| Date | Title | Description |
| 25.06.2024 | Breakthrough T1D-Funded Research Featured at American Diabetes Association 84th Scientific Sessions | NEW YORK, June 25, 2024 /PRNewswire/ -- Breakthrough T1D, formerly JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, gathered with researchers, diabetes professionals, and other leaders in T1D at the America... |
| 28.02.2024 | vTv Therapeutics Announces $51 Million Private Placement from Healthcare-focused Institutional Investors and the JDRF T1D Fund | - |
| 24.10.2023 | Former Novo Nordisk Executive, Dr. Todd Hobbs, joins Diasome Pharmaceuticals as Chief Medical Officer | Dr. Todd Hobbs, Former North American Chief Medical Officer at Novo Nordisk, to Guide Diasome's HDV Platform Expansion The Fund is proud to work alongside the company’s management team – including Dr. Hobbs – as they advance their high impa... |
| 11.05.2023 | Biotech startup DiogenX secures €27.5M to develop therapeutic solutions for Type 1 diabetes | Marseille-based DiogenX, a preclinical-stage biotech company specialising in the development of pancreatic beta-cell modulators for the treatment of diabetes, announced on Wednesday, May 10, that it has raised €27.5M in a Series A round of ... |
| 09.11.2020 | Protomer Gets Boost to Develop Glucose Responsive Insulin | Protomer Technologies Inc., a Pasadena-based biopharmaceutical startup, closed a second round of funding to expand the tech platform it's using to develop insulin that adjusts according to a diabetes patient's blood sugar levels. The undisc... |
| 09.11.2020 | Pasadena Biopharma Startup Protomer Gets an Investment Boost | Protomer Technologies Inc., a Pasadena-based biopharmaceutical startup, closed a second round of funding to expand the tech platform it's using to develop insulin that adjusts according to a diabetes patient's blood sugar levels. The undisc... |
| 05.09.2019 | Veralox Therapeutics Raises $5.4 Million in Seed Funding Co-Led by JDRF T1D Fund and Sanofi Ventures | Funding to Advance Development of Drug Candidates Targeting Heparin-Induced Thrombocytopenia and Type 1 Diabetes |
| 05.09.2019 | Veralox Therapeutics Raises $5.4 Million in Seed Funding Co-Led by JDRF T1D Fund and Sanofi Ventures | FREDERICK, Md.--(BUSINESS WIRE)--Veralox Therapeutics, a preclinical stage company focused on accelerating the development of first-in-class therapeutics for unmet medical needs, today announced it has raised a $5.4 million seed funding rou... |
| 04.10.2018 | Precision medicine needs a business mindset in order to flourish | Precision medicine, also known as personalized medicine, has the potential to transform how we treat — or even cure — cancer and a host of other diseases such as cystic fibrosis, Parkinson’s, and Alzheimer’s. The precision approach to patie... |
| 18.07.2018 | JDRF T1D Fund Appoints Ellias as Managing Director | The JDRF T1D Fund, a venture philanthropy fund focused on accelerating life-changing solutions to treat, prevent, and cure type 1 diabetes (T1D) through catalytic commercial investments, today announced that Katie Ellias has joined the fund... |
Show more